Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Clin Chem. 2016 Nov 3;63(1):288–296. doi: 10.1373/clinchem.2016.261636

Table 3.

Comparison of clinical model fit with addition of GlycA, MS-HDL-P, and GlycA*MS-HDL-P interactions.

AIC Likelihood ratio Χ2a C statisticb
Clinical model 38221 1178 0.72
Clinical model + GlycA 37997 1404 0.75
Clinical model + GlycA + MS-HDL-P 37726 1677 0.78
Clinical model + GlycA + MS-HDL-P + GlycA*MS-HDL-P 37685 1720 0.79
GRACE 26171 686 0.69
GRACE + GlycA 26042 818 0.73
GRACE + GlycA + MS-HDL-P 25825 1037 0.78
GRACE + GlycA + MS-HDL-P + GlycA*MS-HDL-P 25782 1081 0.78
FHS + GlycA 41266 589 0.64
FHS + GlycA + MS-HDL-P 40712 1145 0.74
FHS + GlycA + MS-HDL-P + GlycA*MS-HDL-P 40664 1195 0.75
a

From Cox models: clinical model includes age, sex, race, BMI, diabetes, hypertension, smoking, hyperlipidemia and LDL-P, presence of CAD, and ejection fraction.

b

From linear regression models for 2-year death.